Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib dose-escalation with cisplatin-based chemoradiotherapy for high-risk locally advanced head and neck squamous cell carcinoma
ISRCTN62346992Phase 2Terminated
- Sponsor
- University College London
- Start
- Dec 2011
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of olaparib in head and neck squamous cell carcinoma (HNSCC), sponsored by University College London. Primary endpoint: Frequency of dose-limiting toxicities. Started Dec 2011; status: terminated.
02
Drugs
olaparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN62346992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62346992.